Loading
Life sciences · Journal article
Cells · August 17, 2026
Raises a question worth testing. It does not answer one.
This mechanistic study identifies Ser1258 within the C-terminal intrinsically disordered region of LMTK3 as a regulatory phosphorylation site that modulates kinase domain autoinhibition and oncogenic phenotypes in ER-positive breast cancer cells and xenografts. The work characterizes a molecular mechanism but does not test a clinical hypothesis and provides no patient data.
Mechanistic characterization combining computational modelling, biophysical assays, biochemistry, cell biology, and xenograft models. ER-positive breast cancer cell lines (MCF7); female BALB/c nude mice with orthotopic MCF7 xenografts; no patient population.. Intervention: Phospho-null mutation of Ser1258 in LMTK3; comparison to wild-type LMTK3. Compared with: Wild-type LMTK3; constitutively active LMTK3-KDL313R mutant; control cell lines and vehicle-bearing animals (implied but not explicit).
Two C-terminal regions (residues 688–1095 and 1181–1486) interact with LMTK3 kinase domain LMTK3(1181–1486) shows preferential binding to inactive wild-type kinase domain over constitutively active mutant, consistent with autoinhibition Ser1258 within α-helix 2 (residues 1247–1258) identified as regulatory phosphorylation site by kinase assays and mass spectrometry
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work characterizes a novel molecular mechanism of LMTK3 regulation that may inform future therapeutic strategies targeting LMTK3 in ER-positive breast cancer, but does not provide direct clinical evidence or treatment recommendations at this stage.
This is a mechanistic study using computational modelling, biophysical assays, and cell/animal models to characterize a regulatory phosphorylation site; it raises a mechanism of LMTK3 regulation rather than testing a clinical hypothesis in patients.
As stated by the source record.
Quoted from the source exactly as published.
This work characterizes a novel molecular mechanism of LMTK3 regulation that may inform future therapeutic strategies targeting LMTK3 in ER-positive breast cancer, but does not provide direct clinical evidence or treatment recommendations at this stage.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Lemur tail kinase 3 (LMTK3) is an oncogenic Ser/Thr kinase implicated in breast cancer (BC) progression, therapy resistance, and poor clinical outcomes, yet the molecular mechanisms governing its regulation remain poorly understood, particularly the role of its C-terminal intrinsically disordered region (IDR). Given that IDRs frequently harbour hidden structural motifs that control protein dynamics, we combined computational, biophysical, and biochemical approaches to systematically map regulatory elements within the LMTK3 C-terminus, identifying two regions (residues 688–1095 and 1181–1486) that interact with the LMTK3 kinase domain (LMTK3-KD). Characterisation of these interactions revealed that LMTK31181–1486 displays preferential binding to inactive wild-type LMTK3-KD over a constitutively active mutant (LMTK3-KDL313R), a behaviour consistent with a potential autoinhibitory interaction. Guided by AlphaFold3 modelling, we localised this interaction primarily to a short α-helical motif (α-helix 2; residues 1247–1258) within the C-terminal IDR and subsequently identified Ser1258 within this motif as a candidate regulatory phosphorylation site, using [γ-32P]-ATP kinase assays and mass spectrometry. Phosphorylation at Ser1258 altered interactions between α-helix 2 and the kinase domain, reducing binding to wild-type LMTK3-KD while increasing affinity for LMTK3-KDL313R. Functionally, phospho-null mutation of Ser1258 impaired oestrogen receptor alpha (ERα) upregulation, proliferation, migration, and clonogenicity in ER-positive BC cell lines, and reduced tumour growth in female BALB/c nude mice bearing orthotopic MCF7 xenografts. Together, these findings identify a previously uncharacterised regulatory element within the LMTK3 C-terminus and support a model in which Ser1258 phosphorylation modulates kinase domain interactions and LMTK3-driven oncogenic functions in BC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.